While provider education on biosimilars presents a hurdle for health systems worldwide, patient education is also an area of significant need. During the fifth DIA Biosimilars Conference, held October 22 to 23 in London, United Kingdom, several stakeholders addressed this challenge.
While provider education on biosimilars presents a hurdle for health systems worldwide, patient education is also an area of significant need. During the fifth DIA Biosimilars Conference, held October 22 to 23, 2018, in London, United Kingdom, several stakeholders addressed this challenge.
Reaching the Patient Through the Provider
For Arnold Vulto, PharmD, PhD, FCP, professor emeritus of hospital pharmacy and practical therapeutics as Erasmus University Medical Center in Rotterdam, the Netherlands, provider education must be the first step toward instilling confidence in patients.
The Dutch healthcare system, he explained, has taken a tailored approach to provider education through development of the Biosimilars Toolbox, a joint initiative from the Dutch Association of Hospital Pharmacists and the Federation of Medical Specialists. The toolbox, launched in April 2017 (and so far available only in Dutch), is a practical guide for implementation of biosimilars that includes scientific background material and position papers, information about using biosimilars in new and existing patients, a roadmap for implementing a switch, policies for transitioning, and informational materials for patients.
The toolkit relies on a multi-stakeholder approach that includes everyone involved in a switching program, from providers to patients to hospital staff. It also operates on a “one voice” principle that emphasizes synchronized messaging from all members of a healthcare team to avoid potentially creating a nocebo effect in patients.
Vulto also emphasized the need for shared decision-making with the patient and for gain-sharing structures that will allow those implementing the switch to benefit from cost savings produced through biosimilars.
Vulto is also active in the Dutch Biosimilar Education Program (BOM), a voluntary, no-cost program for health systems that aims to increase knowledge of biosimilars and stimulate prescribing of cost-effective therapies. The BOM program offers an inventory of the hospital’s current situation with respect to biosimilars, including a review of the efficiency of the drug procurement process. It also offers a tailored educational program for all stakeholders, which includes lectures, classes, workshops, and online offerings, as well as biannual assessment of progress.
Combatting Misinformation
According to Hillel Cohen, PhD, executive director of scientific affairs at Sandoz, negative comments that could undermine provider and patient confidence in biosimilars are common.
Cohen pointed to a 2018 physician survey, conducted by FirstWord Pharma, that found that 33% of respondents had heard negative statements about biosimilars, and approximately half of those who had encountered such statements said that they had heard them from reference product sponsors.
Some recent areas that have been subject to misinformation, said Cohen, include quality, the extrapolation of indications, and nonmedical switching.
Cohen has encountered claims that biosimilars are of a lower quality than their references, and that interchangeable products are superior to noninterchangeable biosimilars. However, he pointed out, the same quality standards exist for all biologics in the United States and European Union, and because of advancements in technology, a biosimilar may even have lower immunogenicity or impurity levels than its reference. And while interchangeability studies require multiple switches, the quality of the products is the same.
Cohen also reports having heard claims that the safety and efficacy of extrapolated indications is uncertain, but as he points out, extrapolation has been used for decades in the context of major process changes. Furthermore, extrapolation is based on the totality of the evidence, not on the clinical physiology of one indication versus another. If the structure and function of the molecules are the same, he said, they will have the same effect on the patient.
Perhaps most concerning for Cohen, however, is growing patient anxiety about nonmedical switching. In Cohen’s view, the term “nonmedical switching” should not be applied to the biosimilars context, because patients who switch from a reference to a biosimilar are not receiving a new therapy. To use the term, he said, is to conflate switching among products that have different structures with switching between a reference and a biosimilar, potentially sowing unfounded concerns.
Cohen recounted an FDA advisory committee hearing that he attended, saying that numerous individuals took the floor to voice concerns on nonmedical switching. “When everyone gets up there and talks about the same topic, you know it’s been coordinated,” he said, suggesting that baseless fears are being stoked.
While Cohen acknowledges that “nonmedical switching” has become established in the medical literature, he feels it should be replaced with “transitioning.”
Forging Relationships With Patients
Robert Johnstone, a patient advocate and board member of the European Forum for Good Clinical Practice, challenged the common perception that patients lack awareness of or concern about the need for biosimilars to reduce costs for healthcare systems.
Immediately after a diagnosis with a chronic condition, said Johnstone, patients tend to focus solely on getting the right treatment. Yet as time progresses, patients tend to broaden their perspective from what can help them relieve their symptoms. “They begin to see health in a broader context and how society can afford those treatments,” he said.
“I want to raise the concept of the patient not as a passive recipient of healthcare,” he went on, explaining his vision of what he termed “emancipatory healthcare,” in which understanding one’s own condition and working jointly with others can help the system to improve and find efficiency and sustainability.
For Johnstone, education about biosimilars should not only flow from provider to patient, but also from trained patients to their peers. Educating patient advocates to disseminate reliable information to other patients not only frees up providers from the task, but could also provide a potential employment opportunity for patients with chronic diseases.
Crucially, said Johnstone, other stakeholder groups need to engage patients throughout decision-making processes concerning switches to biosimilars, not merely “parachute a patient into a process to deal with one issue.” Building trust among patients requires time, effort, and a relationship built on shared understanding.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
AAD Posters Examine Clinical Effects of Switching to Ustekinumab, Adalimumab Biosimilars
March 20th 2024Two posters presented at the American Academy of Dermatology (AAD) annual meeting examined the effects of switching from reference ustekinumab and adalimumab to biosimilar versions in patients with different types of psoriasis.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.
Review: Real-World Evidence Confirms Effectiveness and Safety of Adalimumab Biosimilar SB5
March 9th 2024The adalimumab biosimilar SB5 was reported to be as safe and effective as the reference product in a review of randomized controlled trials and real-world studies on immune-mediated inflammatory diseases.